EKF Diagnostics Showcases Range of Diabetes and Hematology POC Devices
|
By LabMedica International staff writers Posted on 01 Aug 2024 |
|
EKF Diagnostics (Cardiff, Wales, UK) is showcasing its range of diabetes and hematology point-of-care (POC) devices and connectivity software at ADLM 2024.
Among its diabetes POC devices, EKF is highlighting the Quo-Lab HbA1c semi-automated desktop POC analyzer for measuring glycated hemoglobin (HbA1c). The semi-automated analyzer has been designed specifically to meet the needs of diabetes clinics and laboratories in settings that demand low cost of operation and ease of use. EKF is also showcasing the Quo-Test fully automated desktop POC analyzer designed for easy and reliable HbA1c measurement for the monitoring and management of diabetes in a POC setting such as diabetes clinics and doctors’ surgeries. This fully automated hemoglobin A1c analyzer uses patented boronate affinity fluorescence quenching technology to measure glycated hemoglobin from a 4 μl sample taken from a capillary or venous whole blood. Also featuring at the show is the STAT-Site WB analyzer for the quantitative determination of β-ketones (Beta-Hydroxybutyrate or β-HB) and glucose in whole blood taken from capillary or venous samples.
Additionally, EKF is presenting its newly launched Biosen C-Line, an advanced version of its industry-leading rapid benchtop glucose and lactate analyzer. The new and updated analyzer has been designed to enhance usability with the latest color, touch screen, and advanced connectivity, enabling the Biosen C-Line to seamlessly connect with hospital and laboratory IT systems, via EKF Link, to ensure patient results are quickly and securely available to clinicians. Visitors to the EKF booth at the show can also experience the EKF Link middleware solution for healthcare providers that is designed to manage their POC analyzers and the generated data on one centralized platform. EKF Link is a flexible, open solution that can be interfaced with most vendors’ POC analyzers to permit the real-time management of data including patient test results, QC results, operator management, and analyzer configuration.
Within its portfolio of hematology POC devices, EKF is highlighting the DiaSpect Tm hand-held hemoglobin analyzer which is now powered by EKF Link, enabling new functions like hematocrit calculation, quality control management, and patient data management functions. The proven technology of DiaSpect Tm delivers laboratory-quality results in one second from the microcuvette being placed into the analyzer. In addition, EKF is featuring the Hemo Control POC hemoglobin analyzer which is designed to provide quantitative, lab-quality hemoglobin results in 25 seconds. Also featuring at the show is the HemataStat II microhematocrit centrifuge that provides a quantitative hematocrit reading for up to six blood samples from one 60-second spin.
Related Links:
EKF Diagnostics
 Assay.jpg)
Latest ADLM 2024 News
- HemoSonics Demonstrates Breakthrough in Point-Of-Care Viscoelastic Hemostasis Testing
- Cytovale Demonstrates 8-Minute Sepsis Diagnostic Test
- Inpeco Launches Next-Generation Total Lab Automation System
- Messe Düsseldorf Promotes International “MEDICAlliance” Portfolio at ADLM 2024
- Tianlong Showcases Latest Products in Molecular Diagnostics, Biochemistry, Immunology and POC Testing
- QuidelOrtho Demonstrates Advanced Diagnostic Laboratory Solutions across Healthcare Continuum
- HORIBA Unveils New Compact Hematology Analyzers with Combined ESR and CBC/Diff
- Beckman Coulter Introduces Latest Innovations in Clinical Diagnostics
- Abbott Demonstrates End to End Laboratory Solutions
- Werfen Introduces GEM Premier 7000 with iQM3 Blood Gas Testing System
- Thermo Fisher Showcases Diagnostics Innovation Across Therapeutic Areas
- Siemens Demonstrates Human-Centered Engineering and Automation for Laboratory Testing
- Roche Showcases Solutions for Laboratories of the Future
- POC Electrical Sensing-Based Blood Testing Technology Unveiled at ADLM 2024
- World's First 5-Minute Real-Time PCR Instrument Debuts at ADLM 2024
- ADLM 2024 Showcases Breakthrough Innovations Shaping Future of Clinical Testing
Channels
Clinical Chemistry
view channel
Blood Hormone Pattern Distinguishes Endometriosis with High Accuracy
Endometriosis occurs when tissue similar to the uterine lining grows outside the womb, triggering inflammation, pain, and scarring. Diagnosis often relies on surgery and, in the UK, takes an average of... Read more
Blood Test Brings Alzheimer’s Biomarker Assessment to Routine Labs
Beckman Coulter Diagnostics has received CE Mark under IVDR for the Access p‑Tau217 assay, a blood test designed to support clinical evaluation of amyloid pathology in patients with signs and symptoms... Read more
Molecular Diagnostics
view channel
Epigenetic Profiling Could Refine Prognosis in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with heterogeneous biology that complicates prognostication and treatment selection. Genetic testing clarifies many drivers, yet it... Read more
Genetic Risk Score Supports Diagnosis and Prognosis in Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) causes progressive, irreversible lung scarring that limits breathing and can lead to death. More than 100,000 Americans live with IPF, and an estimated 30,000–40,000... Read more
Extracellular Vesicle Marker Identifies Early Lung Adenocarcinoma and Predicts Recurrence
Lung cancer remains a leading cause of cancer death, and early-stage disease often produces few symptoms, complicating timely diagnosis and risk stratification. Conventional imaging and tissue biopsy have... Read more
Hematology
view channel
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read more
Immunology
view channel
Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read moreMicrobiology
view channel
CE-Marked Blood Assay Automates Tuberculosis Infection Testing
Tuberculosis continues to pose a major global health challenge, with an estimated 10.7 million people falling ill and 1.23 million deaths in 2024. Roughly one quarter of the world’s population is believed... Read more
Genomic Surveillance Algorithm Improves Early Detection of Emerging Variants
Genomic surveillance is essential for detecting viral variants before they spread widely, yet many public health systems face high costs, uneven capacity, and computational barriers. Existing analytic... Read more
Rapid Gastrointestinal PCR Panels Deliver One-Hour Results
Acute infectious gastroenteritis remains a major cause of illness worldwide, especially in young children, older adults, and immunocompromised patients. Nonspecific symptoms such as diarrhea, vomiting,... Read more
H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention
Health systems increasingly rely on economic evidence to guide cancer prevention strategies. For gastric cancer, selecting screening approaches that can integrate with existing programs is a key policy question.... Read morePathology
view channel
New AI Test Delivers Rapid Breast Cancer Recurrence Predictions
Recurrent breast cancer remains a persistent driver of morbidity and retreatment, and current risk stratification often depends on genomic assays that are costly and slow. Waiting weeks for results can... Read more
EBV Status Helps Predict Survival in Primary CNS Lymphoma
Primary central nervous system lymphoma is a rare malignancy in which tumors arise in the brain and, less often, the spinal cord, eyes, or cerebrospinal fluid. Outcomes are especially variable when the... Read more
Technology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read more
Industry
view channel
Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing
Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Eurobio Scientific Completes Acquisition of CareDx Lab Products Division
Eurobio Scientific has closed the acquisition of CareDx AB in Sweden and its fully owned subsidiaries in the United States and Australia that constitute CareDx’s Lab Products division. The business will... Read more
Blood-Based CRISPR Test for Tuberculosis Gains Regulatory Approval in Colombia
Colombia remains a high-priority setting for tuberculosis, with a growing need for diagnostics that complement existing testing strategies and improve access to earlier diagnosis. Solutions that function... Read more
